376 related articles for article (PubMed ID: 15590878)
1. Fetal toxic effects of angiotensin II receptor antagonists: case report and follow-up after birth.
Bos-Thompson MA; Hillaire-Buys D; Muller F; Dechaud H; Mazurier E; Boulot P; Morin D
Ann Pharmacother; 2005 Jan; 39(1):157-61. PubMed ID: 15590878
[TBL] [Abstract][Full Text] [Related]
2. [Fetal toxicity of angiotensin-II-receptor inhibitors. Case report].
Roger N; Popovic I; Madelenat P; Mahieu-Caputo D
Gynecol Obstet Fertil; 2007 Jun; 35(6):556-60. PubMed ID: 17544313
[TBL] [Abstract][Full Text] [Related]
3. Angiotensin II receptor antagonist treatment during pregnancy.
Alwan S; Polifka JE; Friedman JM
Birth Defects Res A Clin Mol Teratol; 2005 Feb; 73(2):123-30. PubMed ID: 15669052
[TBL] [Abstract][Full Text] [Related]
4. Severe neonatal renal failure after maternal use of angiotensin II type I receptor antagonists.
Sinelli MT; Cattarelli D; Cortinovis S; Maroccolo D; Chirico G
Pediatr Med Chir; 2008; 30(6):306-8. PubMed ID: 19431954
[TBL] [Abstract][Full Text] [Related]
5. Angiotensin II receptor antagonists and heart failure: angiotensin-converting-enzyme inhibitors remain the first-line option.
Prescrire Int; 2005 Oct; 14(79):180-6. PubMed ID: 16285075
[TBL] [Abstract][Full Text] [Related]
6. Gestational therapy with an angiotensin II receptor antagonist and transient renal failure in a premature infant.
Bass JK; Faix RG
Am J Perinatol; 2006 Jul; 23(5):313-7. PubMed ID: 16799914
[TBL] [Abstract][Full Text] [Related]
7. [Transient renal failure in a newborn due angiotensin receptor II antagonist use during pregnancy: report of a case].
Hasbún H J; Valdés R E; San Martín O A; Catalán M J; Salinas Q S; Parra C M
Rev Med Chil; 2008 May; 136(5):624-30. PubMed ID: 18769811
[TBL] [Abstract][Full Text] [Related]
8. Fatal fetal outcome with the combined use of valsartan and atenolol.
Briggs GG; Nageotte MP
Ann Pharmacother; 2001; 35(7-8):859-61. PubMed ID: 11485133
[TBL] [Abstract][Full Text] [Related]
9. Fetal toxicity of valsartan and possible reversible adverse side effects.
Berkane N; Carlier P; Verstraete L; Mathieu E; Heim N; Uzan S
Birth Defects Res A Clin Mol Teratol; 2004 Aug; 70(8):547-9. PubMed ID: 15329835
[TBL] [Abstract][Full Text] [Related]
10. Valsartan. Just a second-line antihypertensive drug.
Can Fam Physician; 1999 Nov; 45():2626-8, 2630-3. PubMed ID: 10587770
[TBL] [Abstract][Full Text] [Related]
11. Prognosis and outcome of pregnancies exposed to renin-angiotensin system blockers.
Spaggiari E; Heidet L; Grange G; Guimiot F; Dreux S; Delezoide AL; ; Muller F
Prenat Diagn; 2012 Nov; 32(11):1071-6. PubMed ID: 22903358
[TBL] [Abstract][Full Text] [Related]
12. [Acute renal failure and hypertension].
Bellido D; Sánchez de la Nieta MD; Vozmediano C; Oteros R; Zarca MA; Nieto J; Rivera F
Nefrologia; 2005; 25(5):563-7. PubMed ID: 16392308
[TBL] [Abstract][Full Text] [Related]
13. Valsartan in chronic heart failure.
Ripley TL
Ann Pharmacother; 2005 Mar; 39(3):460-9. PubMed ID: 15687480
[TBL] [Abstract][Full Text] [Related]
14. Angiotensin II-receptor-antagonists: further evidence of fetotoxicity but not teratogenicity.
Schaefer C
Birth Defects Res A Clin Mol Teratol; 2003 Aug; 67(8):591-4. PubMed ID: 14632309
[TBL] [Abstract][Full Text] [Related]
15. Proteinuria, chronic kidney disease, and the effect of an angiotensin receptor blocker in addition to an angiotensin-converting enzyme inhibitor in patients with moderate to severe heart failure.
Anand IS; Bishu K; Rector TS; Ishani A; Kuskowski MA; Cohn JN
Circulation; 2009 Oct; 120(16):1577-84. PubMed ID: 19805651
[TBL] [Abstract][Full Text] [Related]
16. [Fetal and neonatal effects of maternal treatment with angiotensin converting enzyme inhibitor].
Rhabbour M; Lenoir S; Bouissou F; Rolland M; Fournié A
Arch Pediatr; 1994 May; 1(5):497-500. PubMed ID: 7951836
[TBL] [Abstract][Full Text] [Related]
17. Fetal exposure to lisinopril: neonatal manifestations and management.
Bhatt-Mehta V; Deluga KS
Pharmacotherapy; 1993; 13(5):515-8. PubMed ID: 8247923
[TBL] [Abstract][Full Text] [Related]
18. Effects of the angiotensin II type 1 receptor antagonist valsartan on the expression of superoxide dismutase in hypertensive patients.
Yang HY; Kao PF; Chen TH; Tomlinson B; Ko WC; Chan P
J Clin Pharmacol; 2007 Mar; 47(3):397-403. PubMed ID: 17322151
[TBL] [Abstract][Full Text] [Related]
19. Angiotensin II receptor blocker induced fetopathy: 7 cases.
Hünseler C; Paneitz A; Friedrich D; Lindner U; Oberthuer A; Körber F; Schmitt K; Welzing L; Müller A; Herkenrath P; Hoppe B; Gortner L; Roth B; Kattner E; Schaible T
Klin Padiatr; 2011 Jan; 223(1):10-4. PubMed ID: 21271514
[TBL] [Abstract][Full Text] [Related]
20. Molecular signaling mediated by angiotensin II type 1A receptor blockade leading to attenuation of renal dysfunction-associated heart failure.
Li Y; Takemura G; Okada H; Miyata S; Maruyama R; Esaki M; Kanamori H; Li L; Ogino A; Ohno T; Kondo T; Nakagawa M; Minatoguchi S; Fujiwara T; Fujiwara H
J Card Fail; 2007 Mar; 13(2):155-62. PubMed ID: 17395057
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
